Magrolimab
- Generic Name
- Magrolimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2169232-81-7
- Unique Ingredient Identifier
- 90YIEHRFJ9
- Background
Magrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment
- Conditions
- Recurrent Sezary SyndromeMycosis FungoidesRefractory Mycosis Fungoides and Sezary SyndromeStage IB Mycosis Fungoides and Sezary Syndrome AJCC v8Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8Recurrent Mycosis Fungoides and Sezary SyndromeStage IV Mycosis Fungoides and Sezary Syndrome AJCC v8Recurrent Mycosis FungoidesRefractory Mycosis FungoidesRefractory Sezary Syndrome
- Interventions
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5
- Registration Number
- NCT04541017
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 110
- Registration Number
- NCT04435691
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
- Conditions
- Interventions
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 539
- Registration Number
- NCT04313881
- Locations
- 🇺🇸
Thomas Jefferson University, Sidney Kimmel Cancer Center; Clinical Research Organization, Philadelphia, Pennsylvania, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 34
- Registration Number
- NCT03558139
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 258
- Registration Number
- NCT03248479
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 78
- Registration Number
- NCT02953782
- Locations
- 🇺🇸
Md Anderson, Houston, Texas, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
🇺🇸Wayne State University, Detroit, Michigan, United States
Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 178
- Registration Number
- NCT02953509
- Locations
- 🇺🇸
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.